Importance of antibiotics in the treatment of Covid-19

Authors

DOI:

https://doi.org/10.33448/rsd-v9i10.8481

Keywords:

COVID-19; Antibiotics; Treatment.

Abstract

Antibiotics are being used as an experimental treatment in patients infected with coronavirus, in some patients there was an improvement in signs and symptoms and a reduction in viral load. Based on these facts, studies are being conducted to prove the efficacy of antibiotics, especially macrolides, due to their ability to act at the site of infection, having immunomodulatory action, also having activity against intracellular pathogens. The aim of this study is to verify in the current literature the importance of antibiotics in the treatment of COVID-19 carriers. The methodology used was an integrative review study in lilacs and pubmed databases. The results showed that antibiotics, especially macrolides, showed positive results regarding the reduction of viral load and immunomodulatory function. However, the small number of studies conducted and few patients analyzed are reflections of a challenge to be faced, . In addition, there is a need to understand the mechanisms of action and drug interactions at the molecular level, and phylogenetic studies are also needed.

References

Andreani J., Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., wiurtz, N., Rolain, J., Colson, P., Scola, B., & Raoult, D. (2020). In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microbial pathogenesi 2020: 104228. DOI: https://doi.org/10.1016/j.micpath.2020.104228

Brasil, Ministério da saúde (2020). Secretaria de Políticas de Saúde. Coronavírus, DF.

Comitê de Infecção e Sepse da AMIB (2020). Terapia antimicrobiana empírica na síndrome respiratória aguda grave. Recuperado de https://www.amib.org.br/fileadmin/user_upload/amib/2020/marco/26/19_Terapia_antimicrobiana_empirica_na_sindrome_respiratoria_aguda_grave_pelo_Comite_de_Infeccao_e_Sepse_da_AMIB.pdf

De Araújo Prudente, A. L., Neto, F. C. C. (2020). Protocolo de tratamento do novo coronavírus. Versão 2 (Casos suspeitos/confirmados).

Derendorf H. (2020). Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. International Journal of Antimicrobial Agents 2020: 106007. DOI: https://doi.org/10.1016/j.ijantimicag.2020.106007

El Kik, C. Z. (2020). Combinação de medicamentos é a nova arma contra COVID-19. Boletim P&D. 6(3), 5-6.

Gautret P., et al. (2020). Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel medicine and infectious disease 2020: 101663. DOI: https://doi.org/10.1016/j.tmaid.2020.101663.

Gautret, P., et al. (2020). Hidroxicloroquina e azitromicina como tratamento de COVID19: resultados de um ensaio clínico não randomizado de rótulo aberto. Revista Internacional de Agentes Antimicrobianos 2020: 105949.

Hui, D. S., Lee, N., Chan, P. K., Beigel, J. H. (2018). The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral research, 2018, 150, 202-216. Doi: https://doi.org/10.1016/j.antiviral.2018.01.002.

Malavolta, M., Giacconi, R., Brunetti, D., Proviciali, M., & Maggi, F. (2020). Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats. 4(9), 909. DOI: https://doi.org/10.3390/cells9040909

Millán-oñate, J., Millan, W., Mendoza, L. A., Sánchez, C. G., Fernandez Suarez, H., D. Bonilla Aldana, K., Rodríguez Morales, A. J. (2020). Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Annals of Clinical.

NIH. NTM-CBI. (2020). Pub Chem: Compound Sumary. Azytromicin. 2020a. Disponível em: https:// pubchem.ncbi.nlm.nih.gov/compound/447043.

Quintella, C. M., Silva, L. A. C., Quintella, H. M., Silva, G. H. R., Silva, S. C. R., Uchoa, S. B., Mata, P. M. A. L. T. (2020). Fármacos para COVID-19: muito além da cloroquina (testes clínicos para o coronavírus SARS-CoV-2). Cadernos de Prospecção 2020. 13(3), 599.

Ronco, C., Reis, T., Husain-Syed, F. (2020). Management of acute kidney injury in patients with COVID-19. The Lancet Respiratory Medicine, available online. DOI: https://doi.org/10.1016/S2213-2600(20)30229-0

Sargiacomo, C., Sotgia, F., Lisanti, Michael P. (2020). COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?. Aging (Albany NY). 12(8), 6511. DOI: 10.18632/aging.103001

Spezzani, V., Piunno, A., Iselin, H. (2020). Benign. COVID-19 in an immunocompromised cancer patient-the case of a married couple. Swiss Medical Weekly 2020: 150: 1516. DOI: https://doi.org/10.4414/smw.2020.20246

Ulrich, H., Pillat, Micheli M. (2020). CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Reviews and Reports 2020: 1-7. DOI: https://doi.org/10.1007/s12015-020-09976-7

Downloads

Published

27/09/2020

How to Cite

ANDRADE, L. de M. .; COELHO, J. L. G. .; ALMEIDA, N. dos S. .; LUZ, D. C. R. P. .; MONTE, E. C. .; ARAÚJO, A. F. de .; SAMPAIO, J. R. F. .; CAMPOS, J. R. E.; CAMPOS, J. B. R. .; SANTOS, M. E. C. dos .; ESMERALDO, M. S. .; SANTANA, W. J. de . Importance of antibiotics in the treatment of Covid-19. Research, Society and Development, [S. l.], v. 9, n. 10, p. e2999108481, 2020. DOI: 10.33448/rsd-v9i10.8481. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/8481. Acesso em: 25 apr. 2024.

Issue

Vol. 9 No. 10

Section

Health Sciences

License

Copyright (c) 2020 Lucas de Moraes Andrade; José Leonardo Gomes Coelho; Natália dos Santos Almeida; Dayse Christina Rodrigues Pereira Luz; Emanuel Cardooso Monte; Aretha Feitosa de Araújo; Juliana Ribeiro Francelino Sampaio; José Rafael Eduardo Campos; Jessika Brenda Rafael campos; Maria Eduarda Correia dos Santos; Mikaelle Sales Esmeraldo; Willma José de Santana

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.